Aggarwal R, Rottey S, Bernard-Tessier A, Mellado B, et al. Safety and Efficacy of Tarlatamab in patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study. Clin Cancer Res 2025 Jul 21. doi: 10.1158/1078-0432.CCR-25-1211.
PMID: 40689871